XXXX : a molecular biomarker for head and neck cancer progression.

@entity5 @entity75 @entity213 @entity32565 @entity7944 @entity10933 @entity1141
@entity213 ( @entity213 ) is an aggressive @entity5 in which the early diagnosis of @entity75 is known to directly correlate with increased survival. However, only a portion of biopsies showing @entity1141 will progress to @entity5 , and there are no currently accepted criteria for predicting @entity75 will progress. Therefore, diagnostic protocols that can identify the lesions that are likely to become @entity213 are required. RNA was isolated from normal keratinocytes, the immortalized but nontumorigenic HaCat cell line, and the @entity5 cell lines @entity32565 , SCC-9, SCC-25, and OSCC-3. The RNA was then labeled and used to probe nylon microarray filters that contained a total of 9184 genes (5295 named and 3889 Expression Sequence Tags). Genes whose expression demonstrated a 3-fold or greater change were considered significant. Comparison of expression profiles from normal, HaCat, and four @entity5 cell lines revealed changes in gene expression in a total of 508 genes. Of these, 16 genes showed a consistent loss of expression when comparing normal to immortalized keratinocytes. In addition, 10 genes demonstrated a consistent loss of expression in the @entity5 cell lines only. In this latter group of genes, @entity10933 ( @entity10933 ), a gene whose expression has been linked to cell invasion, was additionally investigated. Altered expression of @entity10933 in the different cultured cells was validated via real-time quantitative-PCR. In addition, immunohistochemical evaluation of biopsy samples revealed a high expression of @entity10933 in both normal and @entity7944 with a marked decrease of expression in areas of the biopsies containing @entity213 . These data demonstrate that genomic profiling can then be used to identify potential genotypic/phenotypic biomarkers that may predict which @entity75 are most likely to progress to @entity213 .
